Lyka Labs (BOM:500259) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 03, 2026)


BOM:500259 Lyka Labs Ltd BOM:500259
49 GF Score
Price ₹72.00
GF Value ₹127.10
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lyka Labs Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Lyka Labs's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

BOM:500259 vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Lyka Labs's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyka Labs Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Lyka Labs's Margin of Safety % (DCF FCF Based) falls into.


BOM:500259
49GF Score
Lyka Labs Ltd BOM:500259
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lyka Labs (BOM:500259) Overvalued in 2026?

Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued. The current stock price of ₹72.00 is trading 43.4% below its estimated GF Value™ of ₹127.10. GuruFocus considers Lyka Labs to be Significantly Undervalued.

Key valuation signals for BOM:500259:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: ₹127.10 vs. price of ₹72.00 (43.4% below fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyka Labs Business Description

Other Exchanges LYKALABS:India
Address 30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
49GF Score

Get the complete analysis for BOM:500259

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹72.00
Price
₹127.10
GF Value